94169-62-7Relevant articles and documents
Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times
Mollica, Luca,Theret, Isabelle,Antoine, Mathias,Perron-Sierra, Fran?oise,Charton, Yves,Fourquez, Jean-Marie,Wierzbicki, Michel,Boutin, Jean A.,Ferry, Gilles,Decherchi, Sergio,Bottegoni, Giovanni,Ducrot, Pierre,Cavalli, Andrea
supporting information, p. 7167 - 7176 (2016/08/24)
Ligand-target residence time is emerging as a key drug discovery parameter because it can reliably predict drug efficacy in vivo. Experimental approaches to binding and unbinding kinetics are nowadays available, but we still lack reliable computational to
1, 3 - DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS
-
Page/Page column 72-73, (2009/01/24)
Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is alkyl, aryl, arylalkyl, heteroaryl, or he
ASPARTYL PROTEASE INHIBITORS
-
Page 194-196, (2010/02/05)
The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.